DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Histidine is an investigational drug.
There have been 23 clinical trials for Histidine. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2015.
The most common disease conditions in clinical trials are Malaria, Falciparum, Macular Edema, and Malaria. The leading clinical trial sponsors are China Medical University Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and National Cardiovascular Center Harapan Kita Hospital Indonesia.
There are two US patents protecting this investigational drug and forty-five international patents.
Recent Clinical Trials for Histidine
|Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission||Malaria Research and Training Center, Bamako, Mali||Phase 4|
|Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission||Radboud University||Phase 4|
|Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission||London School of Hygiene and Tropical Medicine||Phase 4|
Top disease conditions for Histidine
Top clinical trial sponsors for Histidine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Histidine||See Pricing||Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)||See Pricing|
|Histidine||See Pricing||Steviol glucosyltransferases and genes encoding the same||SUNTORY HOLDINGS LIMITED (Osaka, JP)||See Pricing|
|Histidine||See Pricing||Fibrinogen preparations enriched in fibrinogen with an extended alpha chain||Mallinckrodt Pharma IP Trading D.A.C. (Dublin, IE)||See Pricing|
|Histidine||See Pricing||Compositions and methods for inhibition of the JAK pathway||Rigel Pharmaceuticals, Inc. (South San Francisco, CA)||See Pricing|
|Histidine||See Pricing||Compounds that bind to the erythropoietin receptor||See Pricing|
|Histidine||See Pricing||Recombinant yeast having enhanced gamma valerolactone tolerance and methods of use||Wisconsin Alumni Research Foundation (Madison, WI)||See Pricing|
|Histidine||See Pricing||Recombinant host cells comprising phosphoketalase||Butamax Advanced Biofuels LLC (Wilmington, DE)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Histidine||European Patent Office||3157549||2034-06-20||See Pricing|
|Histidine||United Kingdom||201411037||2034-06-20||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|